Full text is available at the source.
A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme
A tumor-targeting system delivering p53 may reduce resistance to chemotherapy and extend survival in mice with aggressive brain tumors
AI simplified
Abstract
Two cycles of treatment with SGT-53 and temozolomide significantly prolonged median survival in an intracranial glioblastoma tumor model.
- SGT-53 chemosensitized both TMZ-sensitive human glioblastoma cell lines (U87 and U251) in laboratory settings.
- Concurrent administration of SGT-53 and temozolomide inhibited tumor growth and increased cell death compared to TMZ alone.
- Temozolomide alone did not significantly affect median survival when compared to a single cycle of treatment.
- Combining SGT-53 with temozolomide may limit the development of resistance to temozolomide in glioblastoma.
AI simplified